Despite the importance of STK11 in lung cancer1, 2, 3 and the observation that therapeutic approaches for other types of cancer harboring genetic alterations have impacted patient care (Supplementary Table S1), targeted therapeutic approaches have not yet been implemented for lung cancer harboring STK11 mutations, a loss-of-function aberration. The gene discussed is STK11; the disease is lung carcinoma.